HM17321 distinguishes itself through a non-incretin mechanism designed to shed fat while preserving lean muscle mass—a critical limitation in many current GLP-1 treatments. Preclinical data suggests the candidate performs effectively both as a standalone therapy and as a complement to existing weight-loss drugs. Hanmi Pharm currently holds responsibility for the ongoing Phase 1 clinical trial, which received U.S. FDA clearance in November 2025. Once this study concludes, Genentech will assume control over subsequent clinical development, including Phase 2 trials.

The agreement structure includes a $190 million upfront payment, with the remainder of the $2.3 billion total contingent upon regulatory and commercial milestones. Beyond these payments, Hanmi remains eligible for tiered royalties on future net sales. Boris L. Zaïtra, head of Roche Corporate Business Development, noted that the partnership reflects a strategy to move beyond simple weight reduction, focusing instead on improving muscle function and overall metabolic health for patients living with obesity and cardiovascular conditions.